Massachusetts-based HotSpot Therapeutics Therapeutics has raised $45m in series A funding from Atlas Venture and Sofinnova Partners to support its creation of drug therapies. CEO Jonathan Montagu said the firm's proprietary technology identifies sites which regulate protein function, before creating novel drug candidates to target the sites. HotSpot Therapeutics will initially focus on enzymes regulating autoimmune diseases and hepatic insulin sensitivity.
Massachusetts-based HotSpot Therapeutics has raised $45m in series A funding from Atlas Venture and Sofinnova Partners to support its creation of drug therapies. CEO Jonathan Montagu said the firm's proprietary technology identifies sites which regulate protein function, before creating novel drug candidates to target the sites. HotSpot will initially focus on enzymes regulating autoimmune diseases and hepatic insulin sensitivity.